Navigation Links
Spectrum Announces bioWorld Distribution Agreement
Date:2/6/2013

New Brunswick, NJ (PRWEB) February 06, 2013

Spectrum Chemicals & Laboratory Products has become a premier distributor for bioWorld, an internationally recognized manufacturer of bioaffinity matrices and reagents for proteomics research. This agreement provides Spectrum access to one of the most comprehensive line of life sciences and biotechnology products for research, including affinity chromatography, molecular biology, cell culture and microbiological reagents.

Spectrum’s major emphasis is on active pharmaceutical ingredients and controlled substances, excipients, dietary supplements, cosmetic ingredients, biochemicals, and a complete line of high-purity solvents for critical analytical applications. "The addition of bioWorld’s Separopore® bioAffinity Matrices for Protein Purification and related buffers and reagents for proteomics expands Spectrum’s current footprint in analytical applications, with a wide range of protein purification reagents not available in the market place. bioWorld’s line of research reagents gives Spectrum access to one of the most comprehensive lines of life sciences and biotechnology products for research, including affinity chromatography, molecular biology, cell culture and microbiology", says Mark Hurd, Spectrum’s General Manager. He adds, "We are committed to increasing our profile across all aspects of life science research from buffers and reagents to high-quality, easy-to-use research kits."

About Spectrum Chemicals & Laboratory Products
Founded in 1971, Spectrum Chemicals & Laboratory Products manufactures and distributes fine chemicals for production and laboratory facilities around the globe. All of Spectrum's worldwide facilities are ISO 900
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
2. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
3. Life Technologies Announces Fourth Quarter and Fiscal 2012 Results
4. United Therapeutics Announces Additional $420 Million Share Repurchase Program
5. Glenmark Announces a New Discovery and the Initiation of IND Enabling Studies of a Novel Monoclonal Antibody Targeting OX40
6. Patheon Announces First Phase of Additional Investment in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
7. Governor Cuomo Announces Continued Growth at Roswell Park Cancer Institute with Regional Economic Development Council Funding; RPCI Center for Personalized Medicine established with CTG (NASDAQ: CTGX) serving as its technology partner
8. Undiscovered Companies Announces A Video Interview Of Hidden Bio-Tech Company Immunotech Laboratories
9. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
10. ComplianceOnline Announces Seminar on Statistical Analysis for Product Development
11. Navigating Cancer Announces Jeff Oberlander as VP, Engineering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... CARLOS, Calif. , May 28, 2015 /PRNewswire/ ... testing, today announced a study published in ... the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test ... the first trimester. A study ... that complete molar pregnancies occur in about 1 ...
(Date:5/28/2015)... BEACH, Fla. , May 28, 2015 ... supporting the anti-cancer potential of its growth hormone-releasing hormone ... at the 2015 ASCO Annual Meeting. The data ... target for Biscayne,s anti-cancer GHRH blockers, is present on ... status. These findings suggest that GHRH antagonists could have ...
(Date:5/28/2015)... Whitehouse Laboratories is excited to announce that ... with PTI Inspection Systems. Whitehouse Labs and PTI will ... method development and validation programs using the most ... includes a more formal program that facilitates cross training ... enables a more effective team approach, especially as it ...
(Date:5/28/2015)... 2015 Clinerion, an eClinical ... and the Alliance for Clinical Research Excellence ... organization operating in the public interest and ... enhance quality, safety, integrity and operational effectiveness ... are pleased to announce their partnership for ...
Breaking Biology Technology:First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 3
... by Launch of Nine Emerging Therapies, Including Five Oral Agents, According ... ... Resources, WALTHAM, Mass., May 29 Decision Resources, one of the,world,s ... highly anticipated launch of the first,oral agents formally approved for multiple sclerosis ...
... Inc. (Nasdaq: MAPP ) today announced the appointment ... Vice President of Human,Resources., Mr. Rosa brings over ... recently, Mr. Rosa worked at Carl Zeiss Meditec, Inc. ... had held since May of,2002. He was an integral ...
... Incorporated,(Nasdaq: GPRO ) announced today that the Company ... specific molecular diagnostic test to detect,high-risk strains of the ... Assay has been CE marked and is currently available,for ... marking and launch of our APTIMA HPV Assay in ...
Cached Biology Technology:Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017 2MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources 2Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 2Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 3Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 4Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 5
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... plants to treat their offspring for disease, research by biologists ... 6 in the journal Ecology Letters. "We ... plants, can reduce parasite infection in the monarchs," says Jaap ... "And we have also found that infected female butterflies prefer ...
... at the Gladstone Institute of Virology and Immunology (GIVI) have ... in the liver is required for the infectious activity of ... new strategy for treating the infection. More than 160 ... is available to prevent further spread of the disease. Current ...
... at the Georgia Institute of Technology and Emory University have ... material into the body to improve the treatment of inflammatory ... become a popular research area because of its potential therapeutic ... a living organism has been an obstacle. In the ...
Cached Biology News:Study finds monarch butterflies use medicinal plants to treat offspring for disease 2Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells 2Researchers develop oral delivery system to treat inflammatory bowel diseases 2Researchers develop oral delivery system to treat inflammatory bowel diseases 3
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
Request Info...
... Panomer 9 oligodeoxynucleotides are ... labeled at the 5' ... Alexa Fluor dyes and ... assessing microarray spot morphology, ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Biology Products: